## Letters

## **RESEARCH LETTER**

## Trends in Reported Marijuana Vaping Among US Adolescents, 2017-2019

Adolescents who vape use portable devices with a heating element to aerosolize a liquid that they inhale. Nicotine use is most common, but tetrahydrocannabinol (the principal psychoactive constituent of marijuana) can also be vaped. Marijuana vaping produces significantly greater physiological and psychological effects compared with traditional smoking methods at the same tetrahydrocannabinol levels, raising concerns about potential health effects. This study reports the prevalence of marijuana vaping for 2019 among US adolescents and the prevalence increases between 2017, 2018, and 2019.

Methods | Monitoring the Future<sup>2</sup> annually surveys nationally representative samples of 8th, 10th, and 12th graders between February and June. Each year schools from 368 randomly selected geographic units throughout the contiguous United States are sampled, with a school successfully recruited from 90% of these units for 2017, 2018, and 2019. Student participation rates were 88% among 8th graders, 86% among 10th graders, and 80% among 12th graders.

Analyses were based on the question "On how many days (if any) have you vaped marijuana" with the time periods of "during the last 30 days," "during the last 12 months," and "in your lifetime." In 2019, the word "days" in the stem question replaced the word "occasions," which was used in 2017 and 2018. In 2019 "near-daily" marijuana vaping was measured for the first time and indicated use on "20+ days" during the past

Part 3 of   Part					Increase From	Р	Increase From	Р	Increase From
No. of 8th graders <sup>b</sup> 4869         4465         8701           Prevalence,%(95%C)         1.6 (1.3-2.1)         2.6 (2.0-3.4)         3.9 (3.3-4.7)         1.0 (0.2-1.7)         .010         1.3 (0.4-2.2)         .006         2.3 (1.5-3.1)           No. of 10th graders <sup>b</sup> 4412         4666         9026		2017	2018	2019	2017 to 2018	Value	2018 to 2019	Value	2017 to 2019 <sup>a</sup>
Prevalence, (9(95%C))         1.6 (1.3-2.1)         2.6 (2.0-3.4)         3.9 (3.3-4.7)         1.0 (0.2-1.7)         0.10 (1.3 (0.4-2.2)         0.06         2.3 (1.5-3.1)           No. of 10th graders <sup>b</sup> 4412         4666         9026           Prevalence, (95%Cl)         4.3 (3.5-5.3)         7.0 (5.9-8.3)         12.6 (11.1-14.3)         2.7 (1.3-4.1)         <.001	Past 30 d								
No. of 10th gradersb         4412         4666         9026           Prevalence, (95%Cl)         4.3 (3.5-5.3)         7.0 (5.9-8.3)         12.6 (11.1-14.3)         2.7 (1.3-4.1)         <.001	No. of 8th graders <sup>b</sup>	4869	4465	8701					
Prevalence, % (95% CI)         4.3 (3.5-5.3)         7.0 (5.9-8.3)         12.6 (11.1-14.3)         2.7 (1.3-4.1)         <.0.01         5.6 (3.7-7.5)*         <.0.01         8.3 (6.5-10.1)           No. of 12th graders*         4073         4247         8314	Prevalence,% (95% CI)	1.6 (1.3-2.1)	2.6 (2.0-3.4)	3.9 (3.3-4.7)	1.0 (0.2-1.7)	.010	1.3 (0.4-2.2)	.006	2.3 (1.5-3.1)
No. of 12th graders	No. of 10th graders <sup>b</sup>	4412	4666	9026					
Prevalence, % (95% CI)         5.0 (4.1-6.0)         7.5 (6.2-8.9)         14.0 (12.6-15.5)         2.5 (1.0-4.0)         <.001         6.5 (4.7-8.4)°         <.001         9.0 (7.2-10.9)           Past 12 mo         No. of 8th gradersb         4878         4471         8701	Prevalence, % (95% CI)	4.3 (3.5-5.3)	7.0 (5.9-8.3)	12.6 (11.1-14.3)	2.7 (1.3-4.1)	<.001	5.6 (3.7-7.5) <sup>c</sup>	<.001	8.3 (6.5-10.1)
Past 12 mo           No. of 8th graders <sup>b</sup> 4878         4471         8701           Prevalence, % (95%Cl)         3.0 (2.5-3.7)         4.4 (3.6-5.4)         7.0 (6.0-8.2)         1.3 (0.3-2.3)         0.09         2.6 (1.3-3.9)         <.001	No. of 12th graders <sup>b</sup>	4073	4247	8314					
No. of 8th graders <sup>b</sup> 4878         4471         8701           Prevalence, % (95% CI)         3.0 (2.5-3.7)         4.4 (3.6-5.4)         7.0 (6.0-8.2)         1.3 (0.3-2.3)         0.09         2.6 (1.3-3.9)         <.001	Prevalence, % (95% CI)	5.0 (4.1-6.0)	7.5 (6.2-8.9)	14.0 (12.6-15.5)	2.5 (1.0-4.0)	<.001	6.5 (4.7-8.4) <sup>c</sup>	<.001	9.0 (7.2-10.9)
Prevalence, % (95% CI)         3.0 (2.5-3.7)         4.4 (3.6-5.4)         7.0 (6.0-8.2)         1.3 (0.3-2.3)         .009         2.6 (1.3-3.9)         <.001         4.0 (2.7-5.3)           No. of 10th graders <sup>b</sup> 4422         4671         9033	Past 12 mo								
No. of 10th gradersb 4422 4671 9033  Prevalence, % (95% CI) 8.1 (6.9-9.6) 12.4 (10.8-14.1) 19.4 (17.4-21.5) 4.2 (2.2-6.3) <.001 7.0 (4.8-9.2) <.001 11.3 (8.7-13.9)  No. of 12th gradersb 4072 4253 8312  Prevalence, % (95% CI) 9.5 (8.1-11.2) 13.1 (11.4-15.1) 20.8 (19.0-22.8) 3.6 (1.4-5.7) <.001 7.7 (5.4-10.0)c <.001 11.3 (8.7-13.9)  Lifetime  No. of 8th gradersb 4907 4507 8747  Prevalence, % (95% CI) 4.0 (3.3-4.9) 5.5 (4.6-6.7) 9.0 (7.8-10.4) 1.5 (0.3-2.7) .012 3.5 (2.0-5.0) <.001 5.0 (3.5-6.5)  No. of 10th gradersb 4449 4712 9068  Prevalence, % (95% CI) 9.8 (8.5-11.4) 14.2 (12.6-16.0) 21.8 (19.8-24.0) 4.4 (2.3-6.5) <.001 7.6 (5.3-9.9) <.001 12.0 (9.4-14.6)  No. of 12th gradersb 4104 4303 8365  Prevalence, % (95% CI) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) <.001 8.1 (5.7-10.5)c <.001 11.8 (9.0-14.7)  Near Dailyd  No. of 8th gradersb 8701  Prevalence, % (95% CI) .0.8 (0.6-1.2)  No. of 10th gradersb 9026  Prevalence, % (95% CI) .0.8 (0.6-1.2)  No. of 12th gradersb 8314	No. of 8th graders <sup>b</sup>	4878	4471	8701					
Prevalence, % (95% CI)         8.1 (6.9-9.6)         12.4 (10.8-14.1)         19.4 (17.4-21.5)         4.2 (2.2-6.3)         <.001         7.0 (4.8-9.2)         <.001         11.3 (8.7-13.9)           No. of 12th gradersb         4072         4253         8312	Prevalence, % (95% CI)	3.0 (2.5-3.7)	4.4 (3.6-5.4)	7.0 (6.0-8.2)	1.3 (0.3-2.3)	.009	2.6 (1.3-3.9)	<.001	4.0 (2.7-5.3)
No. of 12th gradersb 4072 4253 8312  Prevalence, % (95% Cl) 9.5 (8.1-11.2) 13.1 (11.4-15.1) 20.8 (19.0-22.8) 3.6 (1.4-5.7) < .001 7.7 (5.4-10.0)c < .001 11.3 (8.7-13.9)  Lifetime  No. of 8th gradersb 4907 4507 8747  Prevalence, % (95% Cl) 4.0 (3.3-4.9) 5.5 (4.6-6.7) 9.0 (7.8-10.4) 1.5 (0.3-2.7) .012 3.5 (2.0-5.0) < .001 5.0 (3.5-6.5)  No. of 10th gradersb 4449 4712 9068  Prevalence, % (95% Cl) 9.8 (8.5-11.4) 14.2 (12.6-16.0) 21.8 (19.8-24.0) 4.4 (2.3-6.5) < .001 7.6 (5.3-9.9) < .001 12.0 (9.4-14.6)  No. of 12th gradersb 4104 4303 8365  Prevalence, % (95% Cl) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) < .001 8.1 (5.7-10.5)c < .001 11.8 (9.0-14.7)  Near Dailyd No. of 8th gradersb 8701  Prevalence, % (95% Cl) 8701  Prevalence, % (95% Cl) 9026  Prevalence, % (95% Cl) 8314	No. of 10th graders <sup>b</sup>	4422	4671	9033					
Prevalence, % (95% CI)       9.5 (8.1-11.2)       13.1 (11.4-15.1)       20.8 (19.0-22.8)       3.6 (1.4-5.7)       <.001       7.7 (5.4-10.0)c       <.001       11.3 (8.7-13.9)         Lifetime       No. of 8th gradersb       4907       4507       8747       8747       8747       8747       8747       8748       8747       8748       8749       8749       9.0 (7.8-10.4)       1.5 (0.3-2.7)       .012       3.5 (2.0-5.0)       <.001       5.0 (3.5-6.5)       5.0 (3.5-6.5)       <.001       7.6 (5.3-9.9)       <.001       5.0 (3.5-6.5)       <.001       7.6 (5.3-9.9)       <.001       12.0 (9.4-14.6) <td>Prevalence, % (95% CI)</td> <td>8.1 (6.9-9.6)</td> <td>12.4 (10.8-14.1)</td> <td>19.4 (17.4-21.5)</td> <td>4.2 (2.2-6.3)</td> <td>&lt;.001</td> <td>7.0 (4.8-9.2)</td> <td>&lt;.001</td> <td>11.3 (8.7-13.9)</td>	Prevalence, % (95% CI)	8.1 (6.9-9.6)	12.4 (10.8-14.1)	19.4 (17.4-21.5)	4.2 (2.2-6.3)	<.001	7.0 (4.8-9.2)	<.001	11.3 (8.7-13.9)
Lifetime       No. of 8th gradersb       4907       4507       8747         Prevalence, % (95% CI)       4.0 (3.3-4.9)       5.5 (4.6-6.7)       9.0 (7.8-10.4)       1.5 (0.3-2.7)       .012       3.5 (2.0-5.0)       <.001	No. of 12th graders <sup>b</sup>	4072	4253	8312					
No. of 8th graders <sup>b</sup> 4907 4507 8747  Prevalence, % (95% Cl) 4.0 (3.3-4.9) 5.5 (4.6-6.7) 9.0 (7.8-10.4) 1.5 (0.3-2.7) .012 3.5 (2.0-5.0) <.001 5.0 (3.5-6.5)  No. of 10th graders <sup>b</sup> 4449 4712 9068  Prevalence, % (95% Cl) 9.8 (8.5-11.4) 14.2 (12.6-16.0) 21.8 (19.8-24.0) 4.4 (2.3-6.5) <.001 7.6 (5.3-9.9) <.001 12.0 (9.4-14.6)  No. of 12th graders <sup>b</sup> 4104 4303 8365  Prevalence, % (95% Cl) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) <.001 8.1 (5.7-10.5) <sup>c</sup> <.001 11.8 (9.0-14.7)  Near Daily <sup>d</sup> No. of 8th graders <sup>b</sup> 8701  Prevalence, % (95% Cl) 0.8 (0.6-1.2)  No. of 10th graders <sup>b</sup> 9026  Prevalence, % (95% Cl) 3.0 (2.3-4.0)  No. of 12th graders <sup>b</sup> 8314	Prevalence, % (95% CI)	9.5 (8.1-11.2)	13.1 (11.4-15.1)	20.8 (19.0-22.8)	3.6 (1.4-5.7)	<.001	7.7 (5.4-10.0) <sup>c</sup>	<.001	11.3 (8.7-13.9)
Prevalence, % (95% CI)	Lifetime								
No. of 10th graders <sup>b</sup> 4449 4712 9068  Prevalence, % (95% Cl) 9.8 (8.5-11.4) 14.2 (12.6-16.0) 21.8 (19.8-24.0) 4.4 (2.3-6.5) <.001 7.6 (5.3-9.9) <.001 12.0 (9.4-14.6)  No. of 12th graders <sup>b</sup> 4104 4303 8365  Prevalence, % (95% Cl) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) <.001 8.1 (5.7-10.5) <sup>c</sup> <.001 11.8 (9.0-14.7)  Near Daily <sup>d</sup> No. of 8th graders <sup>b</sup> 8701  Prevalence, % (95% Cl) 0.8 (0.6-1.2)  No. of 10th graders <sup>b</sup> 9026  Prevalence, % (95% Cl) 3.0 (2.3-4.0)  No. of 12th graders <sup>b</sup> 8314	No. of 8th graders <sup>b</sup>	4907	4507	8747					
Prevalence, % (95% CI) 9.8 (8.5-11.4) 14.2 (12.6-16.0) 21.8 (19.8-24.0) 4.4 (2.3-6.5) < .001 7.6 (5.3-9.9) < .001 12.0 (9.4-14.6)  No. of 12th graders <sup>b</sup> 4104 4303 8365  Prevalence, % (95% CI) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) < .001 8.1 (5.7-10.5) <sup>c</sup> < .001 11.8 (9.0-14.7)  Near Daily <sup>d</sup> No. of 8th graders <sup>b</sup> 8701  Prevalence, % (95% CI) 0.8 (0.6-1.2)  No. of 10th graders <sup>b</sup> 9026  Prevalence, % (95% CI) 3.0 (2.3-4.0)  No. of 12th graders <sup>b</sup> 8314	Prevalence, % (95% CI)	4.0 (3.3-4.9)	5.5 (4.6-6.7)	9.0 (7.8-10.4)	1.5 (0.3-2.7)	.012	3.5 (2.0-5.0)	<.001	5.0 (3.5-6.5)
No. of 12th graders <sup>b</sup> 4104 4303 8365  Prevalence, % (95% CI) 11.9 (10.2-13.8) 15.6 (13.9-17.6) 23.7 (21.7-25.9) 3.8 (1.5-6.0) <.001 8.1 (5.7-10.5) <sup>c</sup> <.001 11.8 (9.0-14.7)  Near Daily <sup>d</sup> No. of 8th graders <sup>b</sup> 8701  Prevalence, % (95% CI) 0.8 (0.6-1.2)  No. of 10th graders <sup>b</sup> 9026  Prevalence, % (95% CI) 3.0 (2.3-4.0)  No. of 12th graders <sup>b</sup> 8314	No. of 10th graders <sup>b</sup>	4449	4712	9068					
Prevalence, % (95% CI)       11.9 (10.2-13.8)       15.6 (13.9-17.6)       23.7 (21.7-25.9)       3.8 (1.5-6.0)       <.001       8.1 (5.7-10.5)°       <.001       11.8 (9.0-14.7)         No. of 8th gradersb       8701         Prevalence, % (95% CI)       0.8 (0.6-1.2)	Prevalence, % (95% CI)	9.8 (8.5-11.4)	14.2 (12.6-16.0)	21.8 (19.8-24.0)	4.4 (2.3-6.5)	<.001	7.6 (5.3-9.9)	<.001	12.0 (9.4-14.6)
Near Daily <sup>d</sup> No. of 8th graders <sup>b</sup> 8701         Prevalence, % (95% CI)       0.8 (0.6-1.2)         No. of 10th graders <sup>b</sup> 9026         Prevalence, % (95% CI)       3.0 (2.3-4.0)         No. of 12th graders <sup>b</sup> 8314	No. of 12th graders <sup>b</sup>	4104	4303	8365					
No. of 8th graders <sup>b</sup> 8701         Prevalence, % (95% CI)       0.8 (0.6-1.2)         No. of 10th graders <sup>b</sup> 9026         Prevalence, % (95% CI)       3.0 (2.3-4.0)         No. of 12th graders <sup>b</sup> 8314	Prevalence, % (95% CI)	11.9 (10.2-13.8)	15.6 (13.9-17.6)	23.7 (21.7-25.9)	3.8 (1.5-6.0)	<.001	8.1 (5.7-10.5) <sup>c</sup>	<.001	11.8 (9.0-14.7)
Prevalence, % (95% CI)       0.8 (0.6-1.2)         No. of 10th graders <sup>b</sup> 9026         Prevalence, % (95% CI)       3.0 (2.3-4.0)         No. of 12th graders <sup>b</sup> 8314	Near Daily <sup>d</sup>								
No. of 10th graders <sup>b</sup> 9026           Prevalence, % (95% CI)         3.0 (2.3-4.0)           No. of 12th graders <sup>b</sup> 8314	No. of 8th graders <sup>b</sup>			8701					
Prevalence, % (95% CI) 3.0 (2.3-4.0)  No. of 12th graders <sup>b</sup> 8314	Prevalence, % (95% CI)			0.8 (0.6-1.2)					
No. of 12th graders <sup>b</sup> 8314	No. of 10th graders <sup>b</sup>			9026					
•	Prevalence, % (95% CI)			3.0 (2.3-4.0)					
Prevalence, % (95% CI) 3.5 (2.9-4.3)	No. of 12th graders <sup>b</sup>			8314					
	Prevalence, % (95% CI)			3.5 (2.9-4.3)					

 $<sup>^{\</sup>rm a}$  P < .001 for all prevalence increases from 2017 to 2019.

<sup>&</sup>lt;sup>b</sup> The sample sizes were unweighted.

<sup>&</sup>lt;sup>c</sup> One-year prevalence increases from 2018 to 2019 were significantly larger (P < .05) than the increases from 2017 to 2018 for all 10th grade and 12th grade outcomes for past 30-day use.

<sup>&</sup>lt;sup>d</sup> This was the first year near daily use was measured (near daily was defined as use on >20 days during the 30-day period).

30 days. A randomly selected two-thirds sample received the marijuana vaping questions in 2019, and a randomly selected one-third sample received the questions in 2017 and 2018.

Analyses used version 15.1 of Stata MP software (StataCorp) with *svy:* commands to take into account the weights, clustering, and strata of the complex sampling design.<sup>3</sup> Prevalence increases across adjacent years, as well as differences in magnitude of these increases during the study period, were tested for statistical significance with Wald tests using Stata's *lincom* command. Statistical significance was defined as *P* < .05 (2-sided).

The University of Michigan institutional review board approved the study. Informed consent (active or passive per school policy) was obtained from the parents for students who were younger than 18 years and from the students who were aged 18 years or older.

Results | The number of students randomly selected to receive the marijuana vaping questions was 14 560 of 43 703 in 2017, 14 857 of 44 482 in 2018, and 28 346 of 42 531 in 2019.

In 2019, past 30-day prevalence of marijuana vaping was reported by 3.9% (95% CI, 3.3%-4.7%) of 8th graders, 12.6% (95% CI, 11.1%-14.3%) of 10th graders, and 14.0% (95% CI, 12.6%-15.5%) of 12th graders (Table).

Reported past 30-day prevalence levels significantly increased from 2018 to 2019. The absolute increases were 1.3% (95% CI, 0.4%-2.2%; P=.006) in 8th graders, 5.6% (95% CI, 3.7%-7.5%; P<.001) in 10th graders, and 6.5% (95% CI, 4.7%-8.4%; P<.001) in 12th graders. Among 12th graders, this increase was significantly larger than the increase from 2017 to 2018 by an absolute difference of 4.0% (ie, 6.5% -2.5% [95% CI, 1.3%-6.8%]; P=.004). Among 10th graders, the increase was by 2.9% (ie, 5.6% -2.7% [95% CI, 0.1%-5.7%]; P=.04).

Results were similar for use during the past 12 months and lifetime use. Prevalence increases in every year were statistically significant for all grades. For all reporting intervals, the prevalence increases among 12th graders were larger from 2018 to 2019 than from 2017 to 2018 (Table).

In 2019, near daily marijuana vaping was reported by 0.8% (95% CI, 0.6%-1.2%) of 8th graders, 3.0% (95% CI, 2.3%-4.0%) of 10th graders, and 3.5% (95% CI, 2.9%-4.3%) of 12th graders (Table).

**Discussion** | Reported adolescent marijuana vaping increased from 2018 to 2019. The absolute increases from 2018 to 2019 among 12th graders for past 30-day use are the second largest, single-year increases ever tracked by Monitoring the Future for any substance in its 45-year history (increased nicotine vaping from 2017 to 2018 ranks first).<sup>2</sup>

Study limitations include potential for reporting error and the absence of high-school dropouts.

As the number of adolescents who vape marijuana increases, so too does the scope and effect of any associated health consequences, which may include lung injury when using black market formulations.<sup>4</sup> The rapid rise of marijuana vaping indicates the need for new prevention and intervention efforts aimed specifically at adolescents.

Richard A. Miech, PhD Megan E. Patrick, PhD Patrick M. O'Malley, PhD Lloyd D. Johnston, PhD Jerald G. Bachman, PhD

Author Affiliations: Institute for Social Research, University of Michigan, Ann Arbor (Miech, O'Malley, Johnston, Bachman); Institute of Child Development, University of Minnesota, Minneapolis (Patrick).

Accepted for Publication: November 19, 2019.

Corresponding Author: Richard A. Miech, PhD, Institute for Social Research, University of Michigan, 426 Thompson St, Ann Arbor, MI 48104 (ramiech@umich.edu).

Published Online: December 17, 2019. doi:10.1001/jama.2019.20185

**Author Contributions:** Dr Miech had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Miech, Patrick, O'Malley, Bachman.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Miech, Bachman.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Miech, Johnston, Bachman.
Obtained funding: Miech, Patrick, O'Malley, Bachman.
Administrative, technical, or material support: All authors.
Supervision: Miech, Bachman.

Conflict of Interest Disclosures: None reported.

**Funding/Support:** This research was supported by award R01DA001411 from the National Institute on Drug Abuse.

**Role of the Funder/Sponsor:** The National Institute on Drug Abuse had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

- 1. Spindle TR, Cone EJ, Schlienz NJ, et al. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. *JAMA Netw Open*. 2018;1(7):e184841-e184841. doi:10.1001/jamanetworkopen.2018.4841
- 2. Miech RA, Johnston L, O'Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the Future national survey results on drug use, 1975-2018: secondary school students. http://monitoringthefuture.org/pubs/monographs/mtf-vol1\_2018.pdf. Accessed November 17, 2019.
- **3.** Bachman JG, Johnston LD, O'Malley PM, Schulenberg JE, Miech RA. The Monitoring the Future project after four decades: design and procedures: occasional paper #82. http://monitoringthefuture.org/pubs/occpapers/mtf-occ82.pdf. Accessed November 17, 2019.
- 4. US Centers for Disease Control and Prevention. Outbreak of lung injury associated with e-cigarette use, or vaping. https://www.cdc.gov/tobacco/basic\_information/e-cigarettes/severe-lung-disease.html. Accessed November 17, 2019.